Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Negative pressure wound therapy: Data presented by Smith & Nephew Oct. 23 at the Annual Clinical Symposium on Advances in Skin and Wound Care show that gauze-based negative pressure wound therapy significantly reduced wound dimensions in a prospective, multi-center clinical evaluation of 131 non-grafted patients. The weekly reduction rates in wound area, depth and volume were 8.3%, 15.8% and 20.5%, respectively, Smith & Nephew said. There also was a significant reduction in wound exudate levels from baseline to treatment discontinuation, and a significant increase in the percentage area of the wound bed composed of red granulation tissue over the course of treatment. In a subset analysis of 23 patients with split-thickness skin grafts (STSG) treated with NPWT, the average graft "take" was 83%, including an average take of 50% for diabetics and 95% for non-diabetics. Smith & Nephew markets the Renasys line of NPWT devices

You may also be interested in...



Research In Brief

Staar Surgical: The firm is in discussions with FDA on a protocol for the planned Collamer Accommodating Study Team (CAST) II trial for its nanoFLEX Collamer aspheric single-piece intraocular lens (IOL), CEO Barry Caldwell announced June 9 at the Jefferies Global Life Sciences Conference in Manhattan. The study is designed to determine the "accommodating" properties of nanoFLEX. Early results of the first CAST study suggest nanoFLEX provides superior distance-corrected near vision compared to standard IOLs and comparable results to current premium IOLs (1"The Gray Sheet" Nov. 2, 2009). Following completion of CAST II, the company will undertake CAST III, with a "few minor design changes" to nanoFLEX, to support supplemental PMA approval for a claim of "less spectacle dependence, which would then get us into [the] premium channel," Caldwell said

Research In Brief

Staar Surgical: The firm is in discussions with FDA on a protocol for the planned Collamer Accommodating Study Team (CAST) II trial for its nanoFLEX Collamer aspheric single-piece intraocular lens (IOL), CEO Barry Caldwell announced June 9 at the Jefferies Global Life Sciences Conference in Manhattan. The study is designed to determine the "accommodating" properties of nanoFLEX. Early results of the first CAST study suggest nanoFLEX provides superior distance-corrected near vision compared to standard IOLs and comparable results to current premium IOLs (1"The Gray Sheet" Nov. 2, 2009). Following completion of CAST II, the company will undertake CAST III, with a "few minor design changes" to nanoFLEX, to support supplemental PMA approval for a claim of "less spectacle dependence, which would then get us into [the] premium channel," Caldwell said

Research In Brief

AHRQ DES study: "Largest ever real-world study" comparing drug-eluting (DES) and bare metal stents (BMS) demonstrates the former were associated with significantly lower rates of death in Medicare patients undergoing percutaneous coronary intervention, Agency for Healthcare Research and Quality concludes in Feb. 10 research report. The study included 217,675 DES patients and 45,025 BMS patients. At 30 months, unadjusted rates of death were 12.9% for DES and 17.9% for BMS. Rates of myocardial infarction and revascularization were, respectively, 7.3 and 23.0 per 100 patients in the DES group, and 10.0 and 24.5 per 100 patients in the BMS arm. DES patients also had lower rates of adjusted death and MI, with minimal difference in revascularization, stroke or bleeding

Related Content

Topics

UsernamePublicRestriction

Register

MT028122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel